1-bromoethoxy(t-Butyl)dimethylsilane | 140139-06-6

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 1-bromoethoxy(t-Butyl)dimethylsilane
• 英文别名: t-butyldimethylsilyloxyethyl bromide；tert-butyldimethylsilanyloxyethyl bromide；1-(t-Butyldimethylsilyloxy)ethyl bromide；1-bromoethoxy-tert-butyl-dimethylsilane
• CAS: 140139-06-6
• 化学式: C₈H₁₉BrOSi
• 分子量: 239.228
• InChiKey: CFGVKLRMHNYHND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.75
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(三甲基硅氧基)丙烯 、 1-bromoethoxy(t-Butyl)dimethylsilane 以62%的产率得到4-(t-butyldimethylsilyloxy)-2-pentanone
  参考文献：
  名称：

  Antonsen, Oeyvind; Benneche, Tore; Gundersen, Lise-Lotte, Acta Chemica Scandinavica, 1992, vol. 46, # 2, p. 172 - 177

  摘要：

  DOI：
• 作为产物：
  描述：

  <1-(t-butyldimethylsilyloxy)ethyl>tributylstannane 在 溴 作用下， 以 四氯化碳 为溶剂， 反应 0.17h， 生成 1-bromoethoxy(t-Butyl)dimethylsilane
  参考文献：
  名称：

  Antonsen, Oeyvind; Benneche, Tore; Gundersen, Lise-Lotte, Acta Chemica Scandinavica, 1992, vol. 46, # 2, p. 172 - 177

  摘要：

  DOI：

文献信息

• 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Chi Dae Yoon

  公开号：US20100261727A1

  公开（公告）日：2010-10-14

  2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R 1 -R 4 , V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

  2-芳基苯并噻吩衍生物或其药学上可接受的盐，其制备方法以及用作诊断或治疗退行性脑疾病的药物组合物，其中2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，当它们被标记为放射性同位素时，它们可以作为非侵入性技术诊断早期阿尔茨海默病的诊断试剂。式中R1-R4，V，W，X，Y和Z如规范的详细描述中定义。此外，当含有2-芳基苯并噻吩衍生物的药物组合物与低分子量β-淀粉样肽结合化合物结合时，最小化恶性高分子量β-淀粉样沉积物的产生。因此，该药物组合物可用作退行性脑疾病如阿尔茨海默病的治疗剂。
• 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient
  申请人：Chi Dae Yoon

  公开号：US08497260B2

  公开（公告）日：2013-07-30

  2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

  本发明涉及2-芳基苯并噻吩衍生物或其药学上可接受的盐，其制备方法以及含有其作为活性成分的用于诊断或治疗退行性脑病的制药组合物。由于式1中的2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，因此当它们被标记为放射性同位素时，它们可以用于非侵入性技术诊断早期阿尔茨海默病的诊断试剂。其中，R1-R4、V、W、X、Y和Z如规范的详细描述中所定义。此外，当含有2-芳基苯并噻吩衍生物的制药组合物与低分子量β-淀粉样肽结合化合物结合时，可以最小化致恶性高分子量β-淀粉样沉积物的产生。因此，该制药组合物可用作治疗退行性脑病，如阿尔茨海默病的治疗剂。
• Antonsen, Oeyvind; Benneche, Tore; Gundersen, Lise-Lotte, Acta Chemica Scandinavica, 1992, vol. 46, # 2, p. 172 - 177
  作者：Antonsen, Oeyvind、Benneche, Tore、Gundersen, Lise-Lotte、Undheim, Kjell

  DOI：——

  日期：——